Both Molecular Templates Inc. (NASDAQ:MTEM) and AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) are Biotechnology companies, competing one another. We will contrast their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Molecular Templates Inc. and AmpliPhi Biosciences Corporation.

Profitability

Table 2 shows the net margins, return on assets and return on equity of the two firms.

Insider & Institutional Ownership

Roughly 72.5% of Molecular Templates Inc. shares are held by institutional investors while 6.45% of AmpliPhi Biosciences Corporation are owned by institutional investors. Molecular Templates Inc.’s share held by insiders are 0.7%. Competitively, 1.28% are AmpliPhi Biosciences Corporation’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Molecular Templates Inc.’s stock price has bigger growth than AmpliPhi Biosciences Corporation.

Summary

On 5 of the 9 factors AmpliPhi Biosciences Corporation beats Molecular Templates Inc.

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. The company has reported results from two Phase I clinical trials of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients, as well as evaluating the safety of AB-SA01 when administered topically to the intact skin of healthy adults. Its pipeline also includes AB-PA01 for the treatment of pseudomonas aeruginosa lung infections in cystic fibrosis and chronic rhinosinusitis patients. AmpliPhi Biosciences Corporation has a research collaboration agreement with Royal Brompton Hospital; a license agreement with University of Leicester to develop a phage therapy that targets and kills various clinically relevant toxin types of C. difficile; a cooperative research and development agreement with the U.S. Army Medical Research and Materiel Command and the Walter Reed Army Institute of Research to develop and commercialize bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and a clinical trial agreement with the University of Adelaide. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.